Strategic Collaborations

We have a history of establishing value-creating collaborations with partners who bolster our capabilities. 

Our strategic collaborations with leading global pharmaceutical companies allow us to advance our pipeline, validate our technology, and help streamline our efforts in bringing medicines patients in need.

  PRODUCT initiated
Bemarituzumab (FPA144) License and Collaboration Agreement December 2017
Cabiralizumab (FPA008) License and Collaboration Agreement October 2015
Immuno-Oncology March 2014
Fibrosis and CNS March 2013
Respiratory Diseases April 2012